FunPep Company Limited stock analysis
Want to see JP:4881 full AI Analyst Report?
FunPep Company Limited (4881) Stock Price & Analysis
4881 Stock Chart & Stats
- Day’s Range
- JPY 39.00 - JPY 40.00
- 52-Week Range
- JPY 37.00 - JPY 130.00
- Previous Close
- JPY 41.00
- Volume
- N/A
- Average Volume (3M)
- 167.54K
- Market Cap
- JPY 1.98B
- Enterprise Value
- JPY 752.68M
- Total Cash (Recent Filing)
- JPY 1.89B
- Total Debt (Recent Filing)
- JPY 0
- Price to Earnings (P/E)
- ―
- Beta
- 0.75
- Next Earnings
- Feb 17, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance Sheet
A debt-free capital structure reduces refinancing pressure and interest obligations, giving the company greater flexibility while it funds development. This is particularly helpful for an early-stage biotech because it preserves borrowing capacity and limits the risk that lenders constrain strategic choices.
Prior-year Revenue Growth
Revenue growth in 2024 shows the company has previously demonstrated an ability to expand its top line, providing evidence that demand or commercial activity can improve under favorable conditions. This offers a foundation for recovery, although the subsequent 2025 decline makes sustained execution essential.
Earlier Cash-flow Improvement
Improving free cash flow in 2023 and 2024 indicates that cash consumption had temporarily moderated before the latest deterioration. That history suggests operating performance can improve from a weak base, potentially supporting better funding efficiency if management can restore the earlier trend.
Bears Say
Severe Revenue Contraction
A roughly 94% annual revenue collapse signals a severe deterioration in commercial activity and materially weakens the company’s ability to fund operations from customers. Unless reversed, such a contraction can impair scale, reduce operating leverage, and make future financing increasingly important.
Widening Net Losses
The sharp expansion in net losses shows that the company is not yet converting its operations into a sustainable earnings base. Continued losses can erode shareholder equity, restrict strategic investment, and increase dependence on external capital over the next several quarters.
Accelerating Cash Burn
Accelerating operating cash burn means the business is consuming substantially more liquidity while remaining unable to self-fund. Persistent negative free cash flow raises the likelihood of additional financing needs, and any resulting dilution could limit the long-term benefit accruing to existing shareholders.
4881 FAQ
What was FunPep Company Limited’s price range in the past 12 months?
What is FunPep Company Limited’s market cap?
When is FunPep Company Limited’s upcoming earnings report date?
How were FunPep Company Limited’s earnings last quarter?
Is FunPep Company Limited overvalued?
Does FunPep Company Limited pay dividends?
What is FunPep Company Limited’s EPS estimate?
How many shares outstanding does FunPep Company Limited have?
What happened to FunPep Company Limited’s price movement after its last earnings report?
Which hedge fund is a major shareholder of FunPep Company Limited?
What is the TipRanks Smart Score and how is it calculated?
Company Description
FunPep Company Limited
FunPep Company Limited specializes in the discovery and advancement of pharmaceutical drugs, functional cosmetics, and medical devices, leveraging its core technology in functional peptides. The company's development pipeline prominently features SR-0379, a functional peptide designed to address skin ulcers. FunPep is advancing FPP003, an antibody-inducing peptide, which is undergoing Phase II clinical trials for psoriasis in Australia and for ankylosing spondylitis in Japan. Another antibody-inducing peptide, FPP004X, is also in development, targeting pollinosis. Additionally, the company is working on FPP006, a corona peptide vaccine, and FPP005, an antibody-inducing peptide for psoriasis. Established in 2013, FunPep Company Limited operates from its headquarters in Tokyo, Japan.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Toshimi Miyoshi
- Employees
- 15
- Website
- www.funpep.co.jp
- Address
- 7-15, Saito Asagi 7-chome, Ibaraki, OS, 151-0051, JP
FunPep Company Limited (4881) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 1 | 6 | 15 |
| Technical Analysis | 1 | 6 | 3 |
| Moving Averages | 0 | 0 | 12 |

